CJC-1295 no DAC (Mod GRF 1-29) — what the modified GHRH actually does

It also has a half-life of under ten minutes.

The reason is an enzyme called dipeptidyl peptidase IV — DPP-IV — which circulates in the blood and cleaves peptides at specific amino acid positions, particularly after a proline at position two. GHRH has an alanine at position two, which is a DPP-IV cleavage site. Within minutes of release, the endogenous GHRH is already being degraded. This is not a flaw; it's part of the pulse architecture. The signal is meant to be brief. It triggers a GH release event, and then it disappears, allowing somatostatin to assert counter-regulation and the system to reset for the next pulse.

The problem, from a therapeutic standpoint, is that a compound that disappears in under ten minutes after injection is difficult to work with. Sermorelin — the pharmaceutical GHRH analog, which is the first 29 amino acids of endogenous GHRH — shares this vulnerability. The biologically active portion of GHRH is the N-terminal segment; the first 29 amino acids contain the receptor-binding and activation domain. But GHRH(1-29), like full-length GHRH, is still subject to DPP-IV cleavage at position two. Its half-life in circulation is short enough that multiple daily injections are required, and even then, there are meaningful questions about whether the injected peptide survives long enough to produce a reliable GH response in all patients.

CJC-1295 without DAC — also called Modified GRF 1-29, or Mod GRF 1-29 — was developed to solve this problem through a targeted modification strategy. The approach was to keep the first 29 amino acids of GHRH, preserving the receptor-binding domain, but to introduce amino acid substitutions at four positions specifically chosen to resist DPP-IV cleavage and other proteolytic degradation without disrupting the receptor interaction. The four substitutions are at positions 2, 8, 15, and 27. Position 2 is the primary DPP-IV cleavage site; substituting a different amino acid there dramatically slows degradation. Positions 8, 15, and 27 address other degradation vulnerabilities while maintaining the three-dimensional structure the GHRH receptor needs to recognize and bind the compound.

The result is a modified GHRH fragment with substantially improved metabolic stability. The half-life of Mod GRF 1-29 is approximately 30 to 60 minutes in circulation — short enough to preserve pulsatile dynamics, long enough to produce a reliable GH response after subcutaneous injection. This is the key distinction from sermorelin on one end (shorter half-life, more vulnerable to degradation, smaller and more variable GH response in some users) and CJC-1295 with DAC on the other (half-life extended to approximately 6-8 days through a different modification strategy, producing sustained rather than pulsatile GH/IGF-1 elevation).

Mod GRF 1-29 occupies the middle of that spectrum deliberately. The receptor mechanism is identical to endogenous GHRH: it binds GHRH receptors on pituitary somatotrophs, activates adenylyl cyclase, elevates cyclic AMP, and triggers the calcium-dependent exocytosis of GH-containing secretory granules. What changes with Mod GRF 1-29 relative to sermorelin is not the mechanism but the reliability of signal delivery — more of the injected peptide survives long enough to reach the receptor and do its job.

The pulsatile character of the resulting GH release is worth dwelling on because it's what makes the no-DAC version the preferred compound in combination protocols. When Mod GRF 1-29 is injected — typically subcutaneously in the abdomen — the compound is absorbed into systemic circulation over a relatively short window. The GHRH receptor signal it produces is concentrated in time: a pulse of stimulation, not a sustained elevation. The pituitary responds with a GH release event that resembles, in its time course and peak morphology, a naturally occurring GH pulse. Somatostatin can still respond. The feedback loop remains operative. The GH pulse subsides, and the system is available to produce the next natural pulse on its own schedule.

This is precisely the physiology that the no-DAC designation is meant to preserve. It's also why Mod GRF 1-29 pairs naturally with ipamorelin. Ipamorelin acts on the ghrelin receptor through a distinct pathway that converges on GH release. When both are administered simultaneously, each activating a different receptor type on the same pituitary cells, the synergistic GH release is substantially larger than either compound alone — but still pulsatile, still feedback-governed, still physiologically shaped. The GH response looks like a bigger version of a natural pulse, not the sustained flat elevation that exogenous HGH or the DAC-modified version of CJC-1295 would produce.

The nomenclature around CJC-1295 is worth addressing directly because it causes genuine confusion. "CJC-1295" technically refers to the compound with the Drug Affinity Complex modification — the version with a half-life measured in days. "Mod GRF 1-29" or "CJC-1295 no DAC" refers to the version without the DAC modification, which is the standard compound in most GH peptide protocols. In clinical compounding and in most forum and practitioner discussions, "CJC-1295" is often used to mean the no-DAC version — which is imprecise but common enough that it's worth flagging. If you're working with a prescribing provider or reading a protocol, confirming whether CJC-1295 means the DAC or no-DAC version is a practical step worth taking.

Standard dosing for Mod GRF 1-29 in the protocols that have emerged from clinical practice is typically 100 to 200 micrograms per injection, administered subcutaneously. It's almost always dosed alongside ipamorelin — the same syringe, the same injection timing. The typical injection windows are pre-sleep, morning fasted, and post-workout. The insulin consideration applies here as it does with ipamorelin: GH secretion is blunted in the presence of high insulin, so timing injections to low-insulin states (fasted or two to three hours after the last meal) meaningfully affects the magnitude of the GH response.

Neither CJC-1295 no DAC nor ipamorelin is FDA-approved. Both are used in compounding contexts, prescribed through providers who work in the peptide and longevity medicine space, prepared at licensed compounding pharmacies. The mechanistic case for both is well-developed. The formal clinical trial record for the combination in healthy aging adults is not. That gap — between solid mechanism and limited clinical trial completion — is the defining feature of the evidence landscape here, and it's worth holding clearly rather than letting enthusiasm for the pharmacology obscure the incomplete regulatory picture.

What Mod GRF 1-29 represents is an engineered solution to a real problem: how do you deliver the GHRH signal reliably enough to be therapeutically useful, without turning a pulsatile signal into a sustained one? The four amino acid substitutions that distinguish it from sermorelin accomplish precisely this. The result is the most commonly used GHRH analog in peptide protocols not because it's the newest or most sophisticated compound in the space, but because it threads the needle between metabolic stability and physiological pulsatility in a way that matches what most practitioners and researchers working in this area are trying to achieve.